JAK1 and rheumatoid arthritis: The oral JAK1/2 inhibitor Baricitinib which has been clinically approved for the treatment of rheumatoid arthritis, has been demonstrated to induce M2 polarization significantly by directly inhibiting JAK1/STAT3 phosphorylation (114).